September 24 is World Cancer Research Day, a time for patients, caregivers and companies on the forefront of cancer R&D to look back and look ahead. From cancer immunotherapy to precision medicine and the discovery of novel targets and mutations, there is much hope on the horizon, and BioSpace spoke with a few of the people leading… Continue Reading BioSpace: An In-Depth Look at Innovation on Cancer Research Day
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody… Continue Reading GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19
SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal… Continue Reading GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies
SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Generation of recombinant hyperimmune globulins from diverse B cell repertoires,” in the peer-reviewed journal Nature Biotechnology.… Continue Reading GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) — GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR)… Continue Reading GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical… Continue Reading GigaGen Announces Publication in the Peer-Reviewed Journal mAbs
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP),… Continue Reading GigaGen Initiates Large-Scale Manufacturing of First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of… Continue Reading GEN: Drug Targets Identified More Discerningly
A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.
Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus… Continue Reading Fierce Biotech: GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional… Continue Reading BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of… Continue Reading GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,” in the international, peer-reviewed journal Pathogens. This work showcases for the… Continue Reading GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs. The article demonstrates the potential of GigaGen’s machine… Continue Reading GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
Targeted Oncology: Novel CTLA-4 Agents Build on Immunotherapy Foundation, Aim to Improve Efficacy/Safety
GIGA-564 featured in the Next Wave of CTLA-4 Blockade. Read the full article.
GigaGen Licenses ProteoNic’s 2G UNic Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and… Continue Reading GigaGen Licenses ProteoNic’s 2G UNic Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates
BioSpace: An In-Depth Look at Innovation on Cancer Research Day
September 24 is World Cancer Research Day, a time for patients, caregivers and companies on the forefront of cancer R&D to look back and look ahead. From cancer immunotherapy to precision medicine and the discovery of novel targets and mutations, there is much hope on the horizon, and BioSpace spoke with a few of the people leading… Continue Reading BioSpace: An In-Depth Look at Innovation on Cancer Research Day
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody… Continue Reading GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19
GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in bioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” The… Continue Reading GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564
GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies
SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal… Continue Reading GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Generation of recombinant hyperimmune globulins from diverse B cell repertoires,” in the peer-reviewed journal Nature Biotechnology.… Continue Reading GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) — GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR)… Continue Reading GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
BARCELONA, Spain, March 9, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P;NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement with GigaGen Inc. to acquire its remaining 56% share capital for USD 80 million. GigaGen… Continue Reading Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
GigaGen Announces Publication in the Peer-Reviewed Journal mAbs
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical… Continue Reading GigaGen Announces Publication in the Peer-Reviewed Journal mAbs
GigaGen Initiates Large-Scale Manufacturing of First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP),… Continue Reading GigaGen Initiates Large-Scale Manufacturing of First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
GEN: Drug Targets Identified More Discerningly
“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of… Continue Reading GEN: Drug Targets Identified More Discerningly
BioCentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute
GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end. It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera. GigaGen showed… Continue Reading BioCentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute
KPIX-TV (CBS): Bay Area Biotech Company Takes New Approach in COVID-19 Treatment
A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.
Fierce Biotech: GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests
Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus… Continue Reading Fierce Biotech: GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests
BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional… Continue Reading BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel… Continue Reading GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050